Business Wire

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology

Share

Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment of endogenous Cushing’s syndrome in adults. Patients with Cushing’s disease, the most common form of endogenous Cushing’s syndrome, have an increased risk of significant comorbidities, including cardiovascular and cerebrovascular diseases as a result of excessive cortisol levels.1 Data from the large LINC-3 study, which enrolled 137 patients with Cushing’s disease, demonstrate that Isturisa® rapidly reduces mUFC and sustains this reduction alongside improvements in comorbidities, clinical signs and patients’ quality of life over 48 weeks.

“The exciting data, published today, underscore the efficacy and safety of Isturisa® in a prospective setting, and represent a significant advance for the management of patients with Cushing’s disease, a serious and potentially life-threatening rare condition,” said Rosario Pivonello, MD, Professor of Endocrinology at the Federico II University of Naples, Italy. “I would like to thank all the patients who participated in the LINC-3 study, and their families, who have helped to bring this new and welcome treatment option to this underserved patient population.”

The LINC-3 study met its primary endpoint, with significantly more patients maintaining normal mUFC with Isturisa® without a dose increase than placebo (86% vs 29%; P<0.0001) following 8 weeks of randomized withdrawal (week 34). Further analysis of patients’ mUFC response found:

  • Over half (53%) of patients achieved the key secondary endpoint of a normal mUFC after an initial 24 weeks of open-label treatment with Isturisa®, without any dose increase after week 12
  • Majority (72%) of patients had normal mUFC at week 12, and two-thirds (66%) of patients had normal mUFC at the end of the 48-week study
  • Almost all (96%) patients achieved normal mUFC at some point during the study, with a median time to first complete response of 41 days

Decreases in mUFC levels during treatment with Isturisa® were accompanied by improvements in clinical signs and cardiovascular-related risk factors (weight, BMI, blood glucose, blood pressure, and total cholesterol). Isturisa® is well tolerated, with the most common adverse effects in LINC-3 being nausea (42%), headache (34%), fatigue (28%) and adrenal insufficiency (28%).

“The publication of these data in Lancet Diabetes & Endocrinology confirms Isturisa® as an effective new treatment option for patients with Cushing’s syndrome,” said Andrea Recordati, CEO. “Following the recent approval of Isturisa® in the US and EU, we are excited to bring Isturisa® to all of those patients who need it.”

The full manuscript can be accessed online at:
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30240-0/fulltext

About Cushing’s syndrome
Cushing’s syndrome
is caused by an inappropriate and chronic exposure to excessive levels of cortisol. The source of this excess of cortisol can be endogenous or exogenous (ie medication).2 When the excess cortisol production is triggered by a pituitary adenoma (ie. a tumor of the pituitary gland located in the brain) secreting excess adrenocorticotropic hormone (ACTH), the condition of the patient is defined as Cushing’s disease and comprises about 70% of Cushing’s syndrome cases.2,3 It is a rare, serious and difficult-to-treat disease that affects approximately one to two patients per million per year. Prolonged exposure to elevated cortisol levels is associated with considerable morbidity, mortality and impaired quality of life as a result of complications and comorbidities.4 Normalization of cortisol levels is therefore a primary objective in the treatment of Cushing’s syndrome.5

About LINC-3
LINC-3 is a prospective, multicentre, 48-week trial with an 8-week, double-blind, randomized withdrawal phase to evaluate the safety and efficacy of Isturisa® in patients with Cushing’s disease. The primary endpoint in the LINC-3 trial is the proportion of patients randomized to Isturisa® and placebo, separately, at Week 26 with a mUFC ≤ULN at the end of the 8-week randomized withdrawal period (Week 34), without a dose increase during this period. The key secondary endpoint is the proportion of enrolled patients with a mUFC ≤ULN after an initial 24 weeks of open-label treatment with Isturisa® without any dose increase after Week 12. LINC-3 involved 137 patients with persistent or recurrent Cushing’s disease or those with de novo disease who were not candidates for surgery.1

About Isturisa®
Isturisa® is a potent oral inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyses the final step of cortisol biosynthesis in the adrenal gland. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets. Isturisa®, indicated for the treatment of adult patients with endogenous Cushing’s syndrome, is now available in France as the first EU country to launch. Isturisa®was granted marketing authorization by the European Commission on 9 January 2020. Please see prescribing information for detailed recommendations for the use of this product.6

  1. Pivonello R et al. Lancet Diabetes Endocrinol 2020; doi: 10.1016/S2213-8587(20)30240-0 [Epub ahead of print]
  2. Lacroix A et al. Lancet 2015;386:913–27
  3. Nieman LK et al. Am J Med 2005;118:1340–6
  4. Pivonello R et al. Lancet Diabetes Endocrinol 2016;4:611–29
  5. Nieman LK et al. J Clin Endocrinol Metab 2015;100:2807–31
  6. Isturisa® Summary of Product Characteristics, May 2020

About Recordati Rare Diseases
The company’s EMEA headquarters is located in Puteaux, France, with global headquarter offices located in Milan, Italy.

For a full list of products, please click here: www.recordatirarediseases.com/products.

About the Recordati group
Recordati
, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For additional information, please visit our websites:www.recordati.com and https://www.recordatirarediseases.com/ or follow us on LinkedIn or Twitter for company updates.

Contact information

Gordon J Daniels
Head of International Marketing
Telephone: +33 (0)607531337
e-mail: daniels.g@recordati.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global Initiates Expansion into Albania28.10.2020 14:30:00 CETPress release

Andersen Global continues to focus on its expansion strategy in the European region with the addition of KALO & ASSOCIATES in Albania. The firm, founded in 1994 by Managing Partner Perparim Kalo, is a leading law firm in Albania. With a team of eight Partners and 30 professionals, the firm has proven capabilities in banking and finance, corporate, commercial litigation and arbitration, employment, tax, infrastructure, intellectual property, and real estate. In addition to working with large projects and investors and IFIs, including a number of Fortune 500 companies, the firm has contributed to the development of a modern commercial legislation and regulatory framework through involvement in the drafting of laws on secured transactions, financial leasing, pension funds, collective investment funds, telecommunications, concessions, renewable energy and energy efficiency. Additionally, the firm is highly ranked by IFLR1000,Chambers and Legal 500. “As the business environment continues to

Sevan Completes 28,000 Surveys, Reaches Major Milestone28.10.2020 14:00:00 CETPress release

Sevan Multi-Site Solutions, Inc. (Sevan) — a global leader in innovative design, program management, construction services and data analytics — has reached a significant milestone. The company has completed 28,000surveys, adding up to more than 700 million square feet since Sevan’s inception in 2011. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005437/en/ Sevan completes 28,000 surveys, reaches major milestone. More than 700 million square feet surveyed. (Graphic: Business Wire) “Sevan’s surveys have become a thread that runs through many of our program management offerings,” President and CEO Jim Evans said. “One of our strongest traits as a company is that we tailor to the needs of our clients, customize innovative solutions and deliver excellence. It has been incredible to see the growth of our surveys and technology offerings in the past years, and we are grateful we have the opportunity to contribute to the succ

Synergis Adept Named #1 in 21 Rankings on G2’s 2020 Fall Grid Reports28.10.2020 13:21:00 CETPress release

Synergis Software, a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd’s Fall 2020 Grid Reports. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/ Synergis Adept earns 21 top honors on G2 Crowd's 2020 Fall Grid Reports. (Graphic: Business Wire) The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market. Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management. “We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're

Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-1928.10.2020 13:20:00 CETPress release

Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19. The aim of therapy with BI 764198 is to reduce the need for ventilator support, to improve patient recovery rate and ultimately to save lives. Boehringer Ingelheim is committed to fighting COVID-19 and contributing with its expertise and resources to develop new therapeutic options for patients suffering from the virus’ severe complications. “COVID-19 can cause serious lung complications, such as viral pneumonia, and in severe cases can lead to acute respiratory distress syndrome (ARDS) and lung failure,” said Dr. Lorraine B. Ware, Ralph and Lulu Oven Endowed Chair and Professor of Medicine, and Pathology, Microbiology and Immunology, Vanderbilt Uni

First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP28.10.2020 13:03:00 CETPress release

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart’s pumping function, providing peak flows greater than 3.5 L/min. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005398/en/ Impella ECP is the world’s smallest heart pump. (Graphic: Business Wire) The first Impella ECP patient was treated by Amir Kaki, MD, an interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital in Detroit, part of Ascension Michigan. The patient had severe narrowing of his coronary arteries. Dr. Kaki successfully opened the patient’s arteries by performing several percutaneous interventions with support from Impella ECP

Alira Health and Embleema Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life Sciences28.10.2020 13:00:00 CETPress release

Alira Health, a leading international healthcare and life sciences advisory firm, and Embleema, the innovative software provider for patient-driven healthcare data platforms, today announced a strategic partnership to develop next-generation real-world data solutions aimed at accelerating clinical innovation and improving patient outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005026/en/ "Our partnership with Embleema is a critical step in the further development of our real-world evidence capabilities, which connects clinical research, hospital care, and the patient experience,” says Gabriele Brambilla, Chief Executive Officer of Alira Health. Romain Finas, VP of Real World Evidence at Alira Health, adds, “We are excited to offer our clients new solutions for real-world data, which will empower them to better evaluate their treatments and deliver new innovations to patients more quickly.” Robert Chu, Chief Ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom